Moderna (NASDAQ:MRNA) Given New $32.00 Price Target at Morgan Stanley

Key Points

• Moderna's target price has been increased from $31.00 to $32.00 by Morgan Stanley, suggesting a potential upside of 20.30%.
• The current average rating for Moderna's stock is "Hold", with a consensus target price of $41.81 despite mixed ratings from various analysts.
• Shares of Moderna traded down to $26.60 recently, with a reported negative EPS of ($2.13) for the last quarter, indicating ongoing financial challenges.

Moderna (NASDAQ:MRNA - Get Free Report) had its target price boosted by equities research analysts at Morgan Stanley from $31.00 to $32.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Morgan Stanley's price target would suggest a potential upside of 20.30% from the company's current price.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI set a $32.00 target price on shares of Moderna in a research report on Friday, August 1st. Bank of America reduced their target price on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research note on Tuesday, July 22nd. JPMorgan Chase & Co. set a $26.00 target price on shares of Moderna in a research note on Friday, August 1st. Leerink Partners reduced their price objective on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a research note on Friday, August 22nd. Finally, Barclays cut their target price on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research note on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have issued a Hold rating and five have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $41.81.

Moderna Price Performance

Shares of MRNA stock traded down $0.93 during trading hours on Friday, reaching $26.60. The stock had a trading volume of 5,620,430 shares, compared to its average volume of 10,856,220. Moderna has a twelve month low of $23.15 and a twelve month high of $59.73. The firm has a 50-day simple moving average of $25.94 and a 200-day simple moving average of $27.25. The firm has a market capitalization of $10.39 billion, a PE ratio of -3.53 and a beta of 2.01.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. During the same quarter in the prior year, the firm earned ($3.33) EPS. The company's revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Moderna will post -9.61 earnings per share for the current year.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust grew its stake in shares of Moderna by 19.0% in the second quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company's stock valued at $65,000 after buying an additional 375 shares in the last quarter. Probity Advisors Inc. grew its stake in shares of Moderna by 2.6% in the second quarter. Probity Advisors Inc. now owns 14,892 shares of the company's stock valued at $411,000 after buying an additional 377 shares in the last quarter. Deseret Mutual Benefit Administrators grew its stake in shares of Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after buying an additional 392 shares in the last quarter. Amalgamated Bank grew its stake in shares of Moderna by 0.6% in the second quarter. Amalgamated Bank now owns 65,458 shares of the company's stock valued at $1,806,000 after buying an additional 408 shares in the last quarter. Finally, Rothschild Investment LLC grew its stake in shares of Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company's stock valued at $25,000 after buying an additional 446 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.